Structured page family:Cost guide
Abaloparatide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Abaloparatide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Tymlos pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Abaloparatide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$3,500-$4,000/month
Average wholesale price
~$3,200-$3,800/month
Pharmacy acquisition estimate
~$3,000-$3,500/month
Typical negotiated rate
~$2,200-$2,800/month
Price per dose
~$117 per 80 mcg
Annual cost at list price
~$42,000-$48,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $3,200-$4,000/month | Required |
Insurance Coverage Landscape
Commercial plans
~70-85% with documentation
Medicare Part D
Covered
Medicaid
Most states cover with prior auth
VA coverage
On formulary
TRICARE
Covered with prior auth
Employer plan typical tier
Tier 4-5 specialty; coinsurance 25-40%
Prior Authorization Guide
Required Documentation
- •DXA T-score ≤-2.5 with fracture or T-score ≤-3.0
- •Bisphosphonate failure or intolerance (often required)
- •Recent DXA
- •Fracture documentation
Common Denial Reasons
- •No fracture history
- •Bisphosphonate not tried
- •T-score not severe enough
Appeal Template Points
- •Severe osteoporosis
- •Bisphosphonate failure
- •High fracture risk
- •Anabolic therapy indicated
Expected timeline: 1-2 weeks
Savings Programs and Patient Assistance
Tymlos PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Radius Health program
Savings card
copayEligibility: Commercially insured
Savings: May reduce significantly
Income limit: None
Enrollment: simple
Annual cap
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected before patent expiry
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 80 mcg daily | $3,500-$4,000 | $42,000-$48,000 |
Annual Cost Projection
Year 1
$0-$48,000
Year 2
$0-$48,000
Year 3
$0 (transition to antiresorptive)
Assumptions
- •2-year limit
- •Insurance/PAP
Cost-Saving Strategies
- 1.Apply for PAP if uninsured
- 2.Document bisphosphonate failure thoroughly
- 3.Compare to teriparatide pricing — may be similar
- 4.Plan for antiresorptive continuation cost after 2 years
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£250-350/month (~$320-450) | NHS |
Need help comparing abaloparatide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a abaloparatide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Abaloparatide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Abaloparatide Cost FAQ
Sources
- 1. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.J Clin Endocrinol Metab • 2020Claim type: clinicalView source →
- 2. FDA Information on AbaloparatideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.